Oxford BioMedica has signed a three-year contract to manufacture and supply viral vectors to support Boehringer Ingelheimâ€™ s cell and gene therapy pipeline.
Under the terms of the Development and Supply Agreement (DSA), Oxford BioMedica will manufacture batches for German pharmaceutical company Boehringer Ingelheim. The agreement also enables Oxford BioMedica to produce and supply viral vector products in the future.
The manufacturing will take place at Oxford BioMedicaâ€™s Windrush Court site, located in Oxford, UK as well as at one of its three UK manufacturing plants. The three UK manufacturing facilities are all based in Oxford – Harrow House, Yarnton and Oxbox.
â€śOxford BioMedica is a leader in the field of virus-based therapeutics and was chosen because of our previousÂ experience with them,â€ť a spokesperson for Boehringer Ingelheim told BioProcess Insider.
Oxford BioMedica and Boehringer Ingelheim partnered in 2018 to develop a gene therapy treatment for Cystic Fibrosis. The collaboration saw Oxford BioMedica develop and manufacture the candidate alongside material for toxicology studies.
Oxford BioMedicaâ€™s CEO, John Dawson echoed this statement and said the agreement â€śdemonstrates the good progress made in our partnership with Boehringer Ingelheim, which started in 2018.â€ť He continued: â€śWe now have a portfolio of partnerships spread across development of CAR-Ts, TCR-Ts and in vivo gene therapeutics, utilising lentiviral vectors.â€ť
Since May 2020, its Oxbox facility has manufactured AstraZencaâ€™s COVID-19 vaccine AZD-1222. The firm added extra production suites in September last year to be able to produce tens of millions of doses per day.
The firm said its COVID-19 efforts will not affect its current or future partnerships.
â€śThere are no concerns with regards to staff and space due to the current manufacture of the vaccine,â€ť a spokesperson for Oxford Biomedica told us. â€śWe have capacity reserved specifically for the vaccine and do not expect any impact on the Groupâ€™s current or new partnerships.â€ť